Education
About Us
Working with TipRanks
Follow Us
BioNano Genomics Inc (BNGO)
NASDAQ:BNGO
BNGO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.30 - $72.60
Previous CloseN/A
Volume11.48M
Average Volume (3M)154.02K
Market Cap
$9.48M
Enterprise Value$38.48M
Total Cash (Recent Filing)$53.06M
Total Debt (Recent Filing)$87.95M
Price to Earnings (P/E)―
Beta3.30
Next Earnings
Mar 31, 2025EPS Estimate
-5.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-138.63
Shares Outstanding2,732,840
10 Day Avg. Volume99,780
30 Day Avg. Volume154,022
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.24
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap4.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$1.00Price Target Upside-71.18% Downside
Rating ConsensusHold
Number of Analyst Covering0
---
BioNano Genomics News
PremiumPre-Earnings
Is BNGO a Buy, Before Earnings?
PremiumCompany Announcements
BioNano Genomics Ends Sales Agreement with Cowen
PremiumCompany Announcements
BioNano Genomics Executes Significant Reverse Stock Split
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentNear-term catalysts include continued rollout and upgrade cycle of BNGO's next-gen, higher-throughput Stratys system.
Reimbursement ProgressBNGO has made progress on OGM reimbursement, and secured a CPT code from AMA for the use of OGM in cytogenomic genome-wide analysis.
Bears Say
Financial GuidanceBNGO again reduced its 2024 revenue guide to $28-30M, below its prior $32-36M, $36-40M, and $37-41M guides earlier this year.
---
Ownership Overview
7.65% Insiders
28.61% Mutual Funds
4.36% Other Institutional Investors
58.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNGO FAQ
What was BioNano Genomics Inc’s price range in the past 12 months?
BioNano Genomics Inc lowest stock price was $3.30 and its highest was $72.60 in the past 12 months.
What is BioNano Genomics Inc’s market cap?
BioNano Genomics Inc’s market cap is $9.48M.
When is BioNano Genomics Inc’s upcoming earnings report date?
BioNano Genomics Inc’s upcoming earnings report date is Mar 31, 2025 which is in 13 days.
How were BioNano Genomics Inc’s earnings last quarter?
BioNano Genomics Inc released its earnings results on Nov 13, 2024. The company reported -$31.2 earnings per share for the quarter, missing the consensus estimate of -$11.851 by -$19.349.
Is BioNano Genomics Inc overvalued?
According to Wall Street analysts BioNano Genomics Inc’s price is currently Overvalued.
Does BioNano Genomics Inc pay dividends?
BioNano Genomics Inc does not currently pay dividends.
What is BioNano Genomics Inc’s EPS estimate?
BioNano Genomics Inc’s EPS estimate is -5.9.
How many shares outstanding does BioNano Genomics Inc have?
BioNano Genomics Inc has 2,732,840 shares outstanding.
What happened to BioNano Genomics Inc’s price movement after its last earnings report?
BioNano Genomics Inc reported an EPS of -$31.2 in its last earnings report, missing expectations of -$11.851. Following the earnings report the stock price went down -7.586%.
Which hedge fund is a major shareholder of BioNano Genomics Inc?
Currently, no hedge funds are holding shares in BNGO
---
BioNano Genomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-71.18% Downside)
$1.00 (-71.18% Downside)
Blogger Sentiment
Bullish
BNGO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 8.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.32%
12-Months-Change
Fundamentals
Return on Equity
-161.77%
Trailing 12-Months
Asset Growth
-51.97%
Trailing 12-Months
Company Description
BioNano Genomics Inc
BioNano Genomics (BNGO) is a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to conduct genetic analysis and diagnostics. The company operates within the genomics sector, providing cutting-edge solutions for genome mapping and analysis, which are crucial for a wide range of applications including cancer research, genetic disorder diagnosis, and agricultural genomics.
---
BNGO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging financial quarter for Bionano, with significant revenue decline and negative gross margins. However, there are positive signs of operational improvement, particularly in cost reductions, increased consumable sales, and progress in clinical research and reimbursement initiatives. The sentiment is mixed with positive strides in some areas countered by financial setbacks.Read More>---
BNGO Stock 12 Month Forecast
Average Price Target
$1.00
▼(-71.18% Downside)
Technical Analysis
---